For the quarter ended March 2025, Akamai Technologies (AKAM) reported revenue of $1.02 billion, up 2.9% over the same period last year. EPS came in at $1.70, compared to $1.64 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.01 billion, representing a surprise of +0.64%. The company delivered an EPS surprise of +7.59%, with the consensus EPS estimate being $1.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

For the quarter ended March 2025, Match Group (MTCH) reported revenue of $831.18 million, down 3.3% over the same period last year. EPS came in at $0.67, compared to $0.44 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $827.91 million, representing a surprise of +0.39%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.67.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ex ...

Core Insights - Coherent reported a revenue of $1.5 billion for the quarter ended March 2025, reflecting a year-over-year increase of 23.9% and exceeding the Zacks Consensus Estimate of $1.44 billion by 3.97% [1] - The company's EPS for the quarter was $0.91, up from $0.53 in the same quarter last year, surpassing the consensus EPS estimate of $0.86 by 5.81% [1] Revenue Performance - Revenue from Materials was $236.70 million, slightly above the estimated $236.16 million, but down 1% year-over-year [4] - Networking revenues reached $897.30 million, exceeding the average estimate of $842.47 million, marking a significant year-over-year increase of 45% [4] - Lasers generated $363.90 million in revenue, slightly above the estimated $359.34 million, with a year-over-year growth of 3.7% [4] - Instrumentation revenue was $95.62 million, below the average estimate of $100.73 million, representing a decline of 2.7% year-over-year [4] - Communications revenue was $896.99 million, surpassing the estimate of $835.13 million, with a year-over-year increase of 45.7% [4] - Industrial revenue was $439.55 million, slightly above the estimated $429.76 million, reflecting a 4.4% year-over-year increase [4] - Electronics revenue was $65.72 million, below the average estimate of $72.64 million, indicating a year-over-year decline of 10.7% [4] Stock Performance - Coherent's shares have returned +35.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

View all Key Company Metrics for GCM Grosvenor here>>> While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price perfor ...

Core Insights - IQVIA Holdings reported $3.83 billion in revenue for Q1 2025, a year-over-year increase of 2.5% and an EPS of $2.70, up from $2.54 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $3.77 billion by 1.55%, and the EPS also surpassed the consensus estimate of $2.63 by 2.66% [1] Financial Performance Metrics - The backlog stood at $31.5 billion, slightly above the average estimate of $31.43 billion from two analysts [4] - Revenue from Technology & Analytics Solutions was $1.55 billion, exceeding the estimated $1.52 billion, reflecting a 6.4% increase year-over-year [4] - Revenue from Research & Development Solutions reached $2.10 billion, slightly above the $2.08 billion estimate, with a year-over-year change of 0.3% [4] - Revenue from Contract Sales & Medical Solutions was $181 million, below the estimated $183.42 million, showing a year-over-year decline of 4.2% [4] - Segment profit for Technology & Analytics Solutions was $360 million, compared to the estimated $365.56 million [4] - Segment profit for Contract Sales & Medical Solutions was $11 million, below the estimated $15.65 million [4] - Segment profit for Research & Development Solutions was $460 million, compared to the estimated $471.69 million [4] Stock Performance - IQVIA shares have returned -0.5% over the past month, while the Zacks S&P 500 composite increased by 11.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Myriad Genetics reported $195.9 million in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.1% and an EPS of -$0.03 compared to -$0.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $199.96 million by 2.03%, while the EPS exceeded the consensus estimate of -$0.05 by 40% [1] Revenue Performance by Product - Prenatal revenue reached $49.30 million, surpassing the estimated $44.69 million, marking a year-over-year increase of 59.6% [4] - Hereditary Cancer revenue was $86.30 million, below the average estimate of $92.46 million, representing a year-over-year decline of 2% [4] - Pharmacogenomics revenue totaled $31 million, slightly below the estimated $32.46 million, with a year-over-year decrease of 20.3% [4] - Tumor Profiling revenue was $29.30 million, compared to the average estimate of $30.66 million, indicating a year-over-year decline of 5.2% [4] Stock Performance - Myriad's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

For the quarter ended March 2025, International Flavors (IFF) reported revenue of $2.84 billion, down 1.9% over the same period last year. EPS came in at $1.20, compared to $1.13 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $2.83 billion, representing a surprise of +0.29%. The company delivered an EPS surprise of +7.14%, with the consensus EPS estimate being $1.12. View all Key Company Metrics for International Flavors here>>> Shares of International Flavors have ...

For the quarter ended March 2025, First Watch Restaurant Group, Inc. (FWRG) reported revenue of $282.24 million, up 16.4% over the same period last year. EPS came in at -$0.01, compared to $0.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $282.33 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -125.00%, with the consensus EPS estimate being $0.04.While investors scrutinize revenue and earnings changes year-over-year and how th ...

Zimmer Biomet (ZBH) reported $1.91 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.1%. EPS of $1.81 for the same period compares to $1.94 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.89 billion, representing a surprise of +0.88%. The company delivered an EPS surprise of +2.84%, with the consensus EPS estimate being $1.76.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Core Insights - Ardelyx reported $74.11 million in revenue for Q1 2025, a year-over-year increase of 61.1%, but fell short of the Zacks Consensus Estimate by 8.14% [1] - The company posted an EPS of -$0.17, which is a decline from -$0.11 a year ago, resulting in a surprise of -70.00% compared to the consensus estimate of -$0.10 [1] Revenue Breakdown - Product sales netted $67.81 million, below the six-analyst average estimate of $77.61 million, reflecting a year-over-year change of +55.9% [4] - Sales of IBSRELA reached $44.40 million, compared to the average estimate of $53.71 million [4] - Sales of XPHOZAH were $23.41 million, slightly below the estimated $24.55 million [4] - Product supply revenue was $0.25 million, significantly lower than the four-analyst average estimate of $3.70 million, marking a year-over-year decline of 88.1% [4] - Non-cash royalty revenue related to future royalties was $1.03 million, exceeding the average estimate of $0.68 million [4] Stock Performance - Ardelyx shares have returned +12.8% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]